4th Operationalize Expanded Access Programs Summit

Memo

Following the increasing interest in access to investigational medicines from patients, the harmonization of guidance and research on the value of expanded access programs witnesses a critical rise. Back in Boston as the only industry forum defining global regulations for EAP and your definitive networking opportunity to connect with managed access teams from other leading and new companies that are immersing themselves in this evolving field of opportunity and life-changing support. Reunite with 120+ industry experts setting up and leading EAPs at the 4th Operationalize Expanded Access Programs Summit and gain practical take aways on how to construct a reliable system, define a clear exit strategy, understand updated local and global regulations, and determine the role of real-world data to optimize the operationalization of your EAP. Don’t miss out on your opportunity to be amongst physicians, patients and passionate EAP and clinical supply experts from Novartis, Daiichi Sankyo, GSK, AstraZeneca, Gilead, Biogen, Sanofi, Eli Lilly, Regeneron, and many more to discover novel strategies in overcoming operational hurdles and deliver life-saving treatments to patients more efficiently.   URLs:Tickets: https://go.evvnt.com/2071459-2?pid=5569Brochure: https://go.evvnt.com/2071459-3?pid=5569 Date and Time: On Tue, 19 Mar 2024 10:00 - Thu, 21 Mar 2024 16:00 Venue details: The Westin Boston Seaport District, 425 Summer Street, Boston, Massachusetts, 02210, United States Prices:Drug Developer - Pre-Conference Workshop Day Only: USD 1298.00,Drug Developer - Conference Only: USD 2999.00,Drug Developer - Conference + Pre-Conference Workshop Day: USD 4197.00,Academic - Pre-Conference Workshop Day Only: USD 1098.00,Academic - Conference Only: USD 2599.00,Academic - Conference + Pre-Conference Workshop Day: USD 3597.00,Vendor - Conference Only: USD 3699.00,Vendor - Conference + Pre-Conference Workshop Day: USD 5097.00 Speakers: Akash Srivastava, Senior Manager, Medical Affairs Operations, Biogen, Annie Drelles, Director, Head of Office of Medical Access, Global Oncology Medical Affairs, Daiichi Sankyo, Inc., Benjamin Rotz, Associate Vice President, Global Medical Policy Strategy and Operations, Eli Lilly and Co., Cassandra Slader, Global Head of Managed Access Programs, UCB, Claire Ramer, Manager, Global Medical Affairs Managed Access Programs Oncology, GlaxoSmithKline Plc, Claire Wardell, Director, Managed Access, GlaxoSmithKline Plc, David Stein, Senior Director, Medical Study Operations, Regeneron Pharmaceuticals Inc, Deborah Nicodemos, Managed Access Programs Lead, Novartis AG, Dennis Akkaya, Chief Commercial Officer, myTomorrows, Elif Oral, Professor - Department of Internal Medicine, Division of Metabolism Endocrinology and Diabetes (MEND), University of Michigan Health System, Ildiko Csiki, Chief Medical and Strategy Officer, Riboscience, Irfan Mohammed, Director, Chemistry, Manufacturing and Controls Team Lead Product Development and Clinical Supply, Alexion Pharmaceuticals, Jasmina Ahrens, Global Lead, Rare Humanitarian Operations, Sanofi, Jennifer Joe, Global Medical Strategy and Population Health Director, AstraZeneca, Joanie Shea, Director Medical Affairs, Day One Biopharmaceuticals Inc., Julia Peterson, Manager of Process and Systems, Sanofi, Kate Nycz, Head of Annual Retreat, Her ALS Story, Katie Bowen, Expanded Access Coordinator, GlaxoSmithKline Plc, Leah Stavenhagen, Founder and President, Her ALS Story, Maggie McDermott, Senior Specialist, Medical Study Operations, Regeneron Pharmaceuticals Inc, Mallory Fredericks, Senior Manager, Medical Research Operations, SpringWorks Therapeutics, Rachel Harrison, Associate Director, Pre-Approval Access Programs, argenx, Ramona Reichenbach, Head Managed Access Center of Excellence, Novartis AG, Raquel Schneid, Global AD Managed Access/PTA, Novartis AG, Robert Mitchell-Thain, CEO, The PBC Foundation Ltd., Stephanie Ferket, Director, Clinical Project Lead, Alexion Pharmaceuticals, Vilem Guryca, Associate Director, Expanded Access, BeiGene